Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
drugs
4
×
life sciences
national blog main
alnylam pharmaceuticals
boston blog main
rna interference
aminolevulinic acid
boston
boston top stories
fda
givosiran
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
alirocumab
amgen
biotech
cannabidiol
dravet syndrome
epidiolex
evercore isi
evolocumab
fen-phen
fenfluramine
gw pharmaceuticals
heart attack
inclisiran
joseph swartz
lennox-gastaut syndrome
medicines co.
new york
new york blog main
new york top stories
onpattro
patisiran
paul matteis
pcsk9 inhibitors
regeneron pharmaceuticals
What
drug
4
×
pharmaceuticals
4
×
alnylam
data
medicine
rna
ago
fda
interference
market
new
rnai
second
seek
speedy
weeks
approval
approved
based
battle
cannabis
cholesterol
cleared
derivative
epilepsy
evidence
far
form
gw
gw’s
heart
indicated
lasting
long
looms
lowering
marijuana
medco
medicines
nasdaq
Language
Current search:
pharmaceuticals
×
drugs
×
drug
×
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug